A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults

Expert Rev Anti Infect Ther. 2023 Oct 6. doi: 10.1080/14787210.2023.2268281. Online ahead of print.ABSTRACTINTRODUCTION: Darunavir (DRV)/cobicistat (COBI)/emtricitabine (FTC)/tenofovir alafenamide (TAF) is the only protease inhibitor-based single tablet regimen approved for the treatment of HIV infection of adults and pediatric patients weighing at least 40 kg. DRV/COBI/FTC/TAF has demonstrated to be an effective regimen, to have a high genetic barrier to resistance and to be well tolerated.AREAS COVERED: The authors summarize the chemistry and pharmacology of DRV, COBI, FTC and TAF and discuss trials conducted on antiretroviral therapy (ART)-naïve and -experienced people living with HIV (PLWH) designed to evaluate safety, tolerability and efficacy of the single tablet regimen. This work also reports studies comparing DRV/COBI/FTC/TAF with competitive agents in real world settings.EXPERT OPINION: Despite the availability of newer antiretroviral drugs and strategies in the management of HIV infection, including long-acting therapies, DRV/COBI/FTC/TAF is still considered an alternative regimen for the treatment of ART-naïve adults. DRV/COBI/FTC/TAF is an effective, well-tolerated and safe antiretroviral regimen and represents a valid option for people who need to switch therapy due to tolerability issues, such as the onset of neuropsychiatric effects related to integrase strand transfer inhibitors, or virological failure.PMID:37800640 | DOI:10.1080/14787210.2023.2268281
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Authors: Source Type: research